APVO News and Press, Aptevo Therapeutics Inc. From 11/04/20

RealNetworks (RNWK) -12% on Q3 earnings release.Aptevo Therapeutics (APVO) -12%.vTv Therapeutics (VTVT) -8% on reporting baseline characteristics for the enrolled subjects in the ongoing Elevage clinical study of azeliragon as a potential treatment for mild Alzhe...

Gainers: Alaska Communications Systems (ALSK) +58%.Beasley Broadcast (BBGI) +39%.JAKKS Pacific (JAKK) +29%.BioLineRx (BLRX) +27%.Gannett Co (GCI) +25%.Inspire Medical Systems (INSP) +24%.GW Pharmaceuticals (GWPH) +20%.Collectors Universe (CLCT) +20%.Telenav (TNAV) +20%.Aptevo Therap...

Gainers: Inspire Medical Systems (INSP) +24%, GW Pharmaceuticals (GWPH) +15%, Aptevo Therapeutics (APVO) +14%, Galera Therapeutics (GRTX) +11%, DBV Technologies (DBVT) +10%.Losers: Esperion Therapeutics (ESPR) -15%, Aurinia Pharmaceuticals (AUPH)&#...

First Complete Remission Observed in a Patient in Cohort 6 Dosing Continues in Cohort 7 SEATTLE, WA / ACCESSWIRE / November 3, 2020 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on i...

Trial Advancing on Schedule and Second Patient Dosed in Cohort 7 No Evidence of Drug-Induced Anti-Drug Antibodies Observed to Date SEATTLE, WA / ACCESSWIRE / September 1, 2020 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a biotechnology company focused on developing novel immuno-onc...

Aptevo Therapeutics (NASDAQ: APVO ) : Q2 GAAP EPS of -$2.10 beats by $0.02 . More news on: Aptevo Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

Advances Phase 1/1b Clinical Trial of APVO436 for the Treatment of Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome; Cohort 6 Enrollment Complete Presents New Preclinical Data Showing That ALG.APV-527 has Potential for a Favorable Safety Profile Extends Cash ...

Extends Cash Runway into Q3 2021 The Current Cash Balance is Anticipated to Create a Sufficient Timeline to Complete the APVO 436 Phase I(a) Dosing Cohorts Which Pre-Clinical Modelling Predicts May Deliver an Efficacious Dose SEATTLE, WA / ACCESSWIRE / August 6, 2020 / Aptevo Thera...

Aptevo Therapeutics ( APVO +1.9% ) has engaged  Piper Sandler to sell its RUXIENCE and IXINITY royalty streams and milestone payments. More news on: Aptevo Therapeutics Inc., Healthcare stocks news, Read more ...

SEATTLE, WA / ACCESSWIRE / July 21, 2020 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ bispecific technology platform, has engaged Piper Sandler to sell its RUXIENCE ® ...